Chongqing Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as "Chongqing Pharmaceutical Holdings") has subsidiaries primarily engaged in pharmaceutical distribution. According to their operational plans and funding needs, to ensure smooth business operations and meet the continuously expanding scale of operations, Chongqing Pharmaceutical Holdings' subsidiary fund companies and their subsidiaries, along with the holding subsidiary Chongqing Phar
000950SZSE
Announcement on the Financing Plan of Chongqing Pharmaceutical Holdings Subsidiaries for 2026
✨ AI Summary
Chongqing Pharmaceutical Holdings plans to apply for a comprehensive financing credit limit of up to RMB 28.91 billion for its subsidiaries in 2026. This financing aims to support business operations and meet the growing scale of operations. The actual credit limit and terms will depend on approvals from financial institutions, with the financing valid for one year from shareholder approval.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.